通过靶向游离DNA甲基化无创检测神经内分泌前列腺癌
去势抵抗性前列腺癌(CRPC)存在异质性亚型,其中神经内分泌前列腺癌(CRPC-NE)的诊断依赖转移灶活检。研究者开发了一种靶向DNA甲基化检测方法,利用血浆游离DNA(cfDNA)量化肿瘤含量并提供表型证据评分,在独立临床队列(222份血浆样本)中验证,检测病理确诊的CRPC-NE(n=136)的AUC>0.93。甲基化定义的cfDNA肿瘤含量与两项针对侵袭性变异型CRPC和CRPC-NE的前瞻性II期临床试验的临床结局相关。
要点
- 靶向cfDNA甲基化检测可无创识别CRPC-NE,AUC>0.93。
- 甲基化定义的cfDNA肿瘤含量与两项前瞻性II期试验的临床结局相关。
- 该检测有望用于CRPC-NE检测和患者分层。
核心结论
- 数据支持应用靶向DNA甲基化进行CRPC-NE检测和患者分层。
研究设计与样本
- 开发靶向DNA甲基化检测方法,利用血浆cfDNA量化肿瘤含量并提供表型证据评分。
- 在独立临床队列(n=222份血浆样本)中测试设计。
主要发现
- 检测病理确诊的CRPC-NE(n=136)的AUC>0.93。
- 甲基化定义的cfDNA肿瘤含量与两项针对侵袭性变异型CRPC和CRPC-NE的前瞻性II期临床试验的临床结局相关。
关键数值与推荐
- 检测病理确诊的CRPC-NE(n=136)的AUC>0.93。
- 独立临床队列共222份血浆样本。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with phenotypic subtypes that drive therapy response and outcome differences. Histologic transformation to castration-resistant neuroendocrine prostate cancer (CRPC-NE) is associated with distinct epigenetic alterations, including changes in DNA methylation. The current diagnosis of CRPC-NE is challenging and relies on metastatic biopsy. We developed a targeted DNA methylation assay to detect CRPC-NE using plasma cell-free DNA (cfDNA). The assay quantifies tumor content and provides a phenotype evidence score that captures diverse CRPC phenotypes, leveraging regions to inform transcriptional state. We tested the design in independent clinical cohorts (n = 222 plasma samples) and qualified it achieving an AUC > 0.93 for detecting pathology-confirmed CRPC-NE (n = 136). Methylation-defined cfDNA tumor content was associated with clinical outcomes in two prospective phase II clinical trials geared towards aggressive variant CRPC and CRPC-NE. These data support the application of targeted DNA methylation for CRPC-NE detection and patient stratification. SIGNIFICANCE: Neuroendocrine prostate cancer is an aggressive subtype of treatment-resistant prostate cancer. Early detection is important, but the diagnosis currently relies on metastatic biopsy. We describe the development and validation of a plasma cell-free DNA targeted methylation panel that can quantify tumor fraction and identify patients with neuroendocrine prostate cancer noninvasively. This article is featured in Selected Articles from This Issue, p. 384.
引用
- Franceschini GM, Quaini O, Mizuno K, et al. Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation. Cancer Discov. 2024. PMID: 38197680. doi:10.1158/2159-8290.CD-23-0754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。